Program
LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010
Its studies are mostly in Multiple Myeloma, led by Kelonia Therapeutics.
Furthest: phase 1, since Jul 2, 20251 company-led study, 1 open or runningNext primary completion: Mar 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Kelonia Therapeutics | 11 open or running | phase 1since Jul 2, 2025 | Jul 2, 2025 | Mar 2027phase 1 · NCT07075185 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 2, 2025First study: phase 1 study in Multiple MyelomaFirst studyNCT07075185 · 70 planned · United States, Australia
Ahead
- Mar 2027Primary completion: phase 1 study in Multiple MyelomaNCT07075185
TargetBeta
“A gene therapy agent composed of a replication-incompetent, self-inactivating lentiviral vector (LVV) expressing a modified vesicular stomatitis virus (VSV) glycoprotein fusogen and an anti-CD3 single chain variable fragment (scFv), and encapsulating a transgene encoding for a chimeric antigen recep”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| elranatamabrule | Pfizer | phase 4 | 15 |
| linvoseltamabrule | Regeneron Pharmaceuticals | phase 4 | 13 |
| teclistamabrule | Johnson & Johnson | phase 4 | 11 |
| etentamig | AbbVie | phase 3 | 11 |
| ramantamig | Johnson & Johnson | phase 3 | 8 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| cizutamigrule | UCB | phase 2 | 5 |
| vonsetamigrule | Regeneron Pharmaceuticals | phase 2 | 3 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07075185Multiple Myeloma · United States, Australia | 1 | Recruiting | Mar 2027 | 70 |
How it is read
Names in the registry
- “KLN-1010”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.